Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Additionally, Recursion plans to present updated clinical data from the TUPELO trial during a webinar scheduled for December 8, 2025. This presentation will provide further insights into the safety ...
Cathie Wood’s ARK Investment acquired 755,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) on December 19, 2025, according to a report published in TheFly. On December 17, 2025, JPMorgan ...
You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Lauren Edmonds Every time Lauren publishes a story, you’ll get an alert straight to your inbox!
You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Lakshmi Varanasi Every time Lakshmi publishes a story, you’ll get an alert straight to your ...
Hosted on MSN
Recursion Pharmaceuticals projects $100M synergies in 2025 amid advancing pipeline and partnerships
CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results